Cancer Insight

oa Open Access

E-ISSN: 2972-3388

Cancer Insight (CI) is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer.  Cancer Insight aims to disseminate and communicate scientific advancement and impactful discoveries on the field of oncology to researchers, academics, clinicians, and the public worldwide. 

View full aims & scope

Latest Articles More >>
Open Access Journal Article
Bimetallic phosphidethe nanoparticles as photo-enhanced nanozymes for synergistic cancer immunotherapy
by Xingru Zhao
CI  2024 3(3):39; 10.58567/ci03030001 - 15 September 2024
Abstract
Nanozyme with biomimetic enzyme activity has the advantages of good catalytic performance, high stability, and is not easily affected by temperature. However, the application of tumor microenvironment (TME) in the tumor is limited due to its low catalytic activity. Herein, a multifunctional nanozyme based on CuCoP with multivalent metal ions (Cu+/Cu2+ and Co2+/ Co3+) provides a [...] Read more

Open Access Journal Article
Targeted intracellular delivery of BH3 mimetic peptide inhibits BCL-2 activity and prevents breast cancer development
by Zhengdong Yuan , Yiwen Zhang , Xuena Yang  and  Hai Qin
CI  2024 3(2):38; 10.58567/ci03020006 - 15 June 2024
Abstract
Breast cancer, as a malignant tumor with easy metastasis and poor prognosis, threatens the health of women around the world. Increasing studies have shown that the Bcl-2 family of apoptosis-related proteins is often expressed abnormally in breast cancer. The Bcl-2 homology 3 (BH3) mimetic peptide can bind and neutralize Bcl-2, preventing its binding to the apoptosis "effector" [...] Read more

Open Access Review
The Dual Roles of S-Nitrosylation of Proteins in Cancer: Molecular Mechanisms and Recent Advancements
by Yi Wu , Yanqi Li , Tong Wu  and  Hongmei Yang
CI  2024 3(2):37; 10.58567/ci03020005 - 15 June 2024
Abstract
Protein S-nitrosylation (SNO), emerging as an important posttranslational modification, involves covalent addition of nitric oxide (NO) to the sulfur atom of cysteine in proteins. Accumulated evidence suggests that protein SNO plays crucial roles in pathophysiological mechanisms in cancer, which is attracting great attention. However, there are still controversies about whether [...] Read more

Open Access Journal Article
Comprehensive analyses reveal molecular and clinical characteristics of RNA modification writers across 32 cancer types
by Jiayu Ding , Hao Shen , Jiaying Ji , Jiaxing Li , Wenbin Kuang , Zhongrui Shi , Dawei Wang , Yuanyuan Chen , Didi Wan , Xiao Wang  and  Peng Yang
CI  2024 3(2):36; 10.58567/ci03020004 - 15 June 2024
Abstract
Adenosine alterations to RNA, which are largely determined by RNA modification writers (RMWs), are critical for cancer growth and progression. These RMWs can catalyze different types of adenosine modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), alternative polyadenylation (APA), and adenosine-to-inosine (A-to-I) RNA editing. These modifications have pr [...] Read more

Open Access Journal Article
A prognostic aging-related lncRNA risk model correlates with the immune microenvironment in HCC
by Kun Mei , Zilu Chen , Qin Wang , Akbar Ali , Yan Huang  and  Luo Yi
CI  2024 3(2):35; 10.58567/ci03020003 - 09 January 2024
Abstract
Background: Hepatocellular carcinoma (HCC) stands out as one of the most lethal cancers globally, given its complexity, recurrence following surgical resection, metastatic potential, and inherent heterogeneity. In recent years, researchers have systematically elucidated the significance of long non-coding RNA (lncRNA) in the initiation and progression of HCC. The intr [...] Read more
Show Figures

Open Access Journal Article
Correlation between the immune microenvironment and bladder cancer based on a prognostic miRNA risk model
by Kun Mei , Zilu Chen , Le Huang , Joyce Wang  and  Yong Wei
CI  2024 3(2):34; 10.58567/ci03020002 - 04 January 2024
Abstract
Background: Bladder cancer (BLCA), particularly invasive BLCA, has become a medical burden worldwide as it is associated with recurrence and easy metastasis. There are specific differences in the expression of various miRNAs in tumor and normal tissues. Hence, miRNAs can be used as biomarkers for tumor diagnosis and prognostic evaluation. The current study aimed to predict the [...] Read more

Open Access Review
CRISPR-Cas9 Unleashed: Gene-Slicing Adventures in the Cancer Battlefield
by Shivakumar Sonnaila  and  Shilpi Agrawal
CI  2024 2(2):33; 10.58567/ci02020008 - 02 January 2024
Abstract
Cancer, a global health menace, continues to pose significant challenges in terms of incidence and mortality, necessitating innovative therapeutic strategies. Despite existing treatments, the limitations persist, prompting a quest for novel approaches. The emergence of immunotherapy marked a transformative era in solid tumor treatments, yet its efficacy is constrained by advers [...] Read more
Show Figures

Open Access Review
Exploring Longitudinal MRI-Based Deep Learning Analysis in Parkinson’s Patients - A Short Survey Focus on Handedness
by Yuan Gu , Ziyang Wang , Yuli Wang , Yishu Gong  and  Chen Li
CI  2023 3(1):32; 10.58567/ci03010006 - 28 December 2023
Abstract
Parkinson’s Disease (PD) is a prevalent progressive neurodegenerative condition affecting millions globally. Research has found that individuals with PD have a reduced risk of certain cancers, such as colon, lung, and rectal cancers, but an increased risk of brain cancer. Therefore, there is an urgent need for the development of advanced PD diagnostic methods and for inve [...] Read more

Open Access Review
Research progress of nanomedicine for tumor immunotherapy
by Xingyi Wan , Mengyan Jiang  and  Shriya Madan
CI  2023 3(1):31; 10.58567/ci03010005 - 28 December 2023
Abstract
Cancer, a pervasive threat to human health, presents formidable challenges to traditional treatment approaches. Tumor immunotherapy has emerged as a promising strategy for combating malignancies by bolstering the body's immune response to thwart tumor metastasis and recurrence. Nonetheless, the intricacies of tumors, patient heterogeneity, and the presence of tumor-immunosuppre [...] Read more
Show Figures

Open Access Journal Article
LTBP1 promotes the progression of triple negative breast cancer via activating the RhoA/ROCK signaling pathway
by Jingcheng Zhang , Hong Deng  and  Jun Wang
CI  2023 3(2):30; 10.58567/ci03020001 - 26 December 2023
Abstract
The latent transforming growth factor-beta (TGF-β) binding protein 1 (LTBP1) has been implicated in various cellular processes, but its role in triple-negative breast cancer (TNBC) remains unclear. In this study, we investigated the impact of LTBP1 on TNBC progression and its underlying mechanisms. Analysis of online datasets revealed elevated LTBP1 mRNA expression in brea [...] Read more